Literature DB >> 22301564

New and future therapies for lupus nephritis.

Gerald B Appel1.   

Abstract

Based on data from randomized controlled trials over the past decade, oral mycophenolate (CellCept) now rivals intravenous cyclophosphamide (Cytoxan) as a first-line therapy for lupus nephritis, offering similar efficacy but less toxicity. The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22301564     DOI： 10.3949/ccjm.78gr.11004

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  4 in total

1.  ESRD from lupus nephritis in the United States, 1995-2010.

Authors:  Donal J Sexton; Scott Reule; Craig Solid; Shu-Cheng Chen; Allan J Collins; Robert N Foley
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-22       Impact factor: 8.237

Review 2.  Lupus nephritis: review of the literature.

Authors:  Adeel Zubair; Marianne Frieri
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

3.  Comparative Effectiveness of Rituximab and Common Induction Therapies for Lupus Nephritis: A Systematic Review and Network Meta-Analysis.

Authors:  Kang Li; Yanqiu Yu; Yuan Gao; Fei Zhao; Zheng Liang; Junjie Gao
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 7.561

Review 4.  MicroRNAs implicated in the immunopathogenesis of lupus nephritis.

Authors:  Cristen B Chafin; Christopher M Reilly
Journal:  Clin Dev Immunol       Date:  2013-07-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.